
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is well positioned for success in the metabolic disease treatment space with its innovative approach and promising lead product, Revita. The encouraging clinical trial results and potential FDA approval in 2026 provide a strong foundation for the company's future growth. The efficient review process for their device and sufficient funding until 2027 further support the positive outlook for Fractyl Health. However, it is important to consider the standard industry risks that could impact the company's success.
Bears say
Fractyl Health is in a strong position with its lead product candidate, Revita, which holds FDA Breakthrough Device Designation and is currently under review in a pivotal trial. With the recently announced RAPID coverage pathway potentially shortening the timeline for Medicare coverage, Revita's development strategy appears to align well. Early data shows a significant correlation between procedure ablation length and weight maintenance, providing a strong "drug-like" response. However, long-term data is still needed to fully assess the potential for weight regain after discontinuation of GLP-1 treatment.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares